Skip to content
Screener

BioMarin Pharmaceuticals BMRN G&A

G&A at other companies

Regenxbio logo
RegenxbioRGNX
$21.62M+8.7%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$8.53M+23.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$1.28M+281%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$50.83M+43.1%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$8.79M+113%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$13.12M+41.4%

Segments

By segment

See full
Reportable Segment$253.36M+130%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

FAQ

What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.